Ramanomics Raises £1.8M to Identify Pathogens and Map Resistance From a Single Clinical Sample

Ramanomics, a UK diagnostics company, has raised £1.8 million to develop its platform for rapid microbial identification and antimicrobial profiling from clinical samples. The company uses Raman spectroscopy — a technique that analyses the way molecules scatter laser light to generate a unique chemical fingerprint — to identify pathogens directly from clinical specimens and produce an antimicrobial susceptibility profile without requiring the extended culture steps that form the bottleneck of conventional microbiology laboratory testing.

Antimicrobial resistance is one of the most serious threats to global public health. A growing proportion of bacterial infections are caused by organisms that are resistant to some or all of the antibiotics that would previously have been effective against them, and the inappropriate or excessive use of antibiotics — driven in large part by the diagnostic delay that forces clinicians to prescribe empirically rather than on the basis of confirmed pathogen identity and sensitivity — is a major driver of the resistance crisis. In the UK, antimicrobial stewardship programmes have made reducing unnecessary broad-spectrum antibiotic use a clinical and regulatory priority, but achieving this goal requires diagnostic tools that can deliver actionable pathogen and resistance information within a clinically useful timeframe.

Current culture-based susceptibility testing typically takes 24 to 72 hours from sample collection to result — a window during which the clinical decision to initiate antibiotic treatment cannot wait. Ramanomics' technology addresses this by using the chemical signatures encoded in Raman spectra to identify microbial species and characterise their resistance phenotype directly from the sample, dramatically compressing the time to actionable result. Raman spectroscopy is well established as an analytical tool in chemistry and materials science, but applying it to clinical microbiology with the sensitivity and specificity required for diagnostic use requires sophisticated data processing and machine learning models trained on large libraries of microbial spectra — which is where Ramanomics' technological differentiation lies.

The funding will be used to develop the instrument and software platform, build and validate the spectral reference libraries that underpin the AI models, and conduct clinical validation studies required for regulatory submission. Ramanomics is targeting a diagnostics market where speed, accuracy, and antimicrobial stewardship are converging as requirements.

Sources

• Crunchbase — Ramanomics company profile